Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| natural killer cell | 9 studies | 19% ± 4% | |
| non-classical monocyte | 7 studies | 26% ± 9% | |
| conventional dendritic cell | 6 studies | 32% ± 18% | |
| CD16-negative, CD56-bright natural killer cell, human | 5 studies | 20% ± 2% | |
| epithelial cell of proximal tubule | 5 studies | 20% ± 5% | |
| CD8-positive, alpha-beta T cell | 5 studies | 18% ± 2% | |
| ciliated cell | 5 studies | 29% ± 9% | |
| gamma-delta T cell | 5 studies | 22% ± 10% | |
| classical monocyte | 4 studies | 31% ± 8% | |
| B cell | 4 studies | 20% ± 6% | |
| macrophage | 4 studies | 26% ± 5% | |
| epithelial cell | 4 studies | 33% ± 9% | |
| plasmacytoid dendritic cell | 4 studies | 25% ± 5% | |
| pancreatic A cell | 3 studies | 19% ± 2% | |
| CD4-positive, alpha-beta T cell | 3 studies | 20% ± 2% | |
| hematopoietic precursor cell | 3 studies | 24% ± 4% | |
| CD16-positive, CD56-dim natural killer cell, human | 3 studies | 18% ± 2% | |
| intraepithelial lymphocyte | 3 studies | 19% ± 2% | |
| dendritic cell | 3 studies | 44% ± 5% | |
| CD8-positive, alpha-beta memory T cell | 3 studies | 23% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 100% | 582.23 | 2638 / 2642 | 100% | 21.49 | 705 / 705 |
| kidney | 100% | 1573.63 | 89 / 89 | 100% | 30.87 | 898 / 901 |
| thymus | 100% | 781.56 | 653 / 653 | 100% | 28.30 | 602 / 605 |
| esophagus | 100% | 791.56 | 1445 / 1445 | 99% | 37.70 | 182 / 183 |
| ovary | 99% | 418.61 | 179 / 180 | 100% | 26.06 | 430 / 430 |
| breast | 100% | 657.85 | 459 / 459 | 99% | 25.91 | 1110 / 1118 |
| uterus | 99% | 545.56 | 169 / 170 | 100% | 32.73 | 458 / 459 |
| bladder | 100% | 656.14 | 21 / 21 | 99% | 31.93 | 498 / 504 |
| prostate | 100% | 540.98 | 245 / 245 | 98% | 18.21 | 494 / 502 |
| intestine | 100% | 677.34 | 966 / 966 | 98% | 30.60 | 517 / 527 |
| stomach | 99% | 472.72 | 357 / 359 | 99% | 29.95 | 282 / 286 |
| pancreas | 99% | 349.36 | 324 / 328 | 99% | 21.88 | 176 / 178 |
| adrenal gland | 100% | 766.45 | 257 / 258 | 98% | 21.93 | 225 / 230 |
| lung | 97% | 613.43 | 563 / 578 | 100% | 33.03 | 1155 / 1155 |
| skin | 99% | 845.23 | 1796 / 1809 | 92% | 23.80 | 433 / 472 |
| liver | 98% | 380.13 | 222 / 226 | 91% | 13.30 | 368 / 406 |
| adipose | 100% | 708.51 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 41.66 | 29 / 29 |
| spleen | 100% | 826.44 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 32.08 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 9.02 | 1 / 1 |
| blood vessel | 100% | 760.07 | 1331 / 1335 | 0% | 0 | 0 / 0 |
| heart | 98% | 618.19 | 847 / 861 | 0% | 0 | 0 / 0 |
| muscle | 93% | 287.80 | 750 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 74% | 682.08 | 691 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 59% | 8.17 | 47 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005829 | Cellular component | cytosol |
| GO_0005515 | Molecular function | protein binding |
| Gene name | COMMD8 |
| Protein name | COMM domain-containing protein 8 |
| Synonyms | MDS022 |
| Description | FUNCTION: May modulate activity of cullin-RING E3 ubiquitin ligase (CRL) complexes . May down-regulate activation of NF-kappa-B . . |
| Accessions | Q9NX08 ENST00000381571.6 |